Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age

In the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral respons...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Krzysztof Lukaszuk, Amira Podolak, Grzegorz Jakiel, Jolanta Kiewisz, Izabela Woclawek-Potocka, Aron Lukaszuk, Lukasz Rabalski
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 mRNA vaccine Medicine R
Acceso en línea:	https://doaj.org/article/44488c0cebbe403897c936894497d193
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44488c0cebbe403897c936894497d193
record_format	dspace
spelling	oai:doaj.org-article:44488c0cebbe403897c936894497d1932021-11-25T19:10:52ZHumoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age10.3390/vaccines91112772076-393Xhttps://doaj.org/article/44488c0cebbe403897c936894497d1932021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1277https://doaj.org/toc/2076-393XIn the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral response to the half-dose (15 µg, 35 participants between 18 and 55 years old) and to the recommended dose (30 µg, 155 participants) in the two-dose three-week interval schedule would be comparable. Antibody levels were measured by the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, upper detection limit: 2570 BAU/mL) on the day of dose 2 of the vaccine and then 8–10 days later to assess peak response to dose 2. The difference in proportions between the participants who did and did not exceed the upper detection limit 8–10 days after dose 2 was not statistically significant (<i>p</i> = 0.152). We suggest that a half-dose schedule can help to achieve widespread vaccination coverage more quickly and cheaply.Krzysztof LukaszukAmira PodolakGrzegorz JakielJolanta KiewiszIzabela Woclawek-PotockaAron LukaszukLukasz RabalskiMDPI AGarticleSARS-CoV-2COVID-19mRNA vaccineMedicineRENVaccines, Vol 9, Iss 1277, p 1277 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 mRNA vaccine Medicine R
spellingShingle	SARS-CoV-2 COVID-19 mRNA vaccine Medicine R Krzysztof Lukaszuk Amira Podolak Grzegorz Jakiel Jolanta Kiewisz Izabela Woclawek-Potocka Aron Lukaszuk Lukasz Rabalski Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
description	In the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral response to the half-dose (15 µg, 35 participants between 18 and 55 years old) and to the recommended dose (30 µg, 155 participants) in the two-dose three-week interval schedule would be comparable. Antibody levels were measured by the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, upper detection limit: 2570 BAU/mL) on the day of dose 2 of the vaccine and then 8–10 days later to assess peak response to dose 2. The difference in proportions between the participants who did and did not exceed the upper detection limit 8–10 days after dose 2 was not statistically significant (<i>p</i> = 0.152). We suggest that a half-dose schedule can help to achieve widespread vaccination coverage more quickly and cheaply.
format	article
author	Krzysztof Lukaszuk Amira Podolak Grzegorz Jakiel Jolanta Kiewisz Izabela Woclawek-Potocka Aron Lukaszuk Lukasz Rabalski
author_facet	Krzysztof Lukaszuk Amira Podolak Grzegorz Jakiel Jolanta Kiewisz Izabela Woclawek-Potocka Aron Lukaszuk Lukasz Rabalski
author_sort	Krzysztof Lukaszuk
title	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
title_short	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
title_full	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
title_fullStr	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
title_full_unstemmed	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
title_sort	humoral response after vaccination with half-dose of bnt162b2 in subjects under 55 years of age
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/44488c0cebbe403897c936894497d193
work_keys_str_mv	AT krzysztoflukaszuk humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT amirapodolak humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT grzegorzjakiel humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT jolantakiewisz humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT izabelawoclawekpotocka humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT aronlukaszuk humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage AT lukaszrabalski humoralresponseaftervaccinationwithhalfdoseofbnt162b2insubjectsunder55yearsofage
_version_	1718410211704700928

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age

Ejemplares similares